Group B streptococci (GBS) remains a major cause of morbidity and mortality in newborn babies, despite antibiotic therapy. Recent studies suggest that phagocytosis and killing of GBS is ineffective due to a deficiency in anti-GBS antibody. Using an opsonophagocytic bacterial assay and a suckling rat model of GBS sepsis, we analyzed a modified human immunoglobulin for opsonic and protective antibody. Immune globulin (IGIV) prepared for intravenous use (Gamimune®, Cutter Laboratories, Inc.) was highly protective in this experimental GBS model. Using the opsonophagocytic assay, antibody activity to several strains of types Ia, II, and III GBS were also demonstrated with IGIV. To ensure that the IGIV activity was in fact antibody, globulin from IGIV was isolated and analyzed. Purified IgG retained opsonic activityin vitro and also provided protection in experimental GBS disease. Variation in the quantity of IgG necessary for protection was observed in different GBS strains. Since IGIV has opsonic and protective activity against several strains and serotypes of GBS, its intravenous administration may provide a valuable adjunct to standard antibiotic therapy for neonatal GBS infections.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Wilkinson HW: Group B streptococcal infections in humans. Ann Rev Microbiol 32:41–57, 1978
Anthony BF, Okada DM: The emergence of group B streptococci in infections of the newborn infant. Ann Rev Med 28:355–369, 1977
Baker CJ: Group B streptococcal infections: NIH Workshop. J Infect Dis 136:137–152, 1977
Stewardson-Krieger PB, Albrandt K, Nevin T, Kretschmer RR, Gotoff SP: Perinatal immunity to group B hemolytic streptococcus type Ia. J Infect Dis 136:649–654, 1977
Baltimore RS, Kasper DL, Baker CJ, Goroff DK: Antigenic specificity of opsonophagocytic antibodies in rabbit antisera to group B streptococci. J Immunol 118:673–678, 1977
Anthony BF: Immunity to group G streptococci: interaction of serum and macrophages with types Ia. Ib and Ic. J Exp Med 143:1186–1198, 1976
Klesius PH, Zimmerman RA, Mathews JH, Krushak DH: Cellular and humoral immune response to group B streptococci. J Pediatr 83:926–932, 1973
Fischer GW, Lowell GH, Crumrine MH, Bass JW: Demonstration of opsonic activity andin vivo protection against group B streptococci type III by streptococcus pneumoniae type 14 antisera. J Exp Med 148:776–786, 1978
Tieffenberg J, Vogel L, Kretschmer RR, Padnos D, Gotoff SP: Chicken embryo model for type III group B beta hemolytic streptococcal septicemia. Infect Immun 19:481–485, 1978
Lancefield RC, McCarty M, Everly WN: Multiple mouseprotective antibodies directed against group B streptococci: special reference to antibodies effective against protein antigens. J Exp Med 142:165–179, 1975
Baker CJ, Kasper DL: Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 294:753–756, 1976
Hemming VG, Hall RT, Rhodes PG, Shigeoka AO, Hill HR: Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence. J Clin Invest 58:1379–1387, 1976
Evans HE, Akpata SO, Glass L: Serum immunoglobin levels in premature and full-term infants. Am J Clin Pathol 56:416–418, 1971
Shigeoka AO, Hall RT, Hill HR: Blood transfusions in group B streptococcal sepsis. Lancet 1:636–638, 1978
Hirsch JG, Strauss B: Studies on heat-labile opsonin in rabbit serum. J Immunol 29:145, 1964
About this article
Cite this article
Fischer, G.W., Wilson, S.R. & Hunter, K.W. Functional characteristics of a modified immunoglobulin preparation for intravenous administration: Summary of studies of opsonic and protective activity against group B streptococci. J Clin Immunol 2, 31S–35S (1982). https://doi.org/10.1007/BF00918364
- Group B streptococci
- neonatal sepsis
- intravenous immune globulin